Items Tagged with 'Pfizer'
Purchase ceiling raised for two stock picks.
In light of significant recent developments, The Turnaround Letter is raising its maximum buy price for these large cap purchase recommendations.Read More
PFE Complete $11.85 billion Sale
On November 30, Pfizer Inc. (NYSE: PFE) announced that it has completed the sale of its Nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets.
PFE Announces Revenues of $14.0 billion
On November 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2012. Third-quarter 2012 revenues were $14.0 billion, a decrease of 16% compared with $16.6 billion in the year-ago quarter, which reflects an operational decline of $1.9 billion, or 12%, and the unfavorable impact of foreign exchange of $699 million, or 4%.
PFE Reports Second Quarter 2012 Revenues of $15.1 Billion
On July 31, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2012.
PFE Obtains FDA Approval for Lyrica
On June 21, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Lyrica® (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.
PFE Reports 7% Revenue Decrease
On May 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2012.
PFE to Divest Nutrition Business
On April 23, 2012, Pfizer Inc. (NYSE: PFE) announced that it has entered into an agreement to divest its Nutrition business to Nestle for $11.85 billion in cash.
Pfizer Buys Vitamin C Icon
On February 27, 2012, Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp....
On February 1, 2012, Pfizer Inc. (NYSE: PFE) announced that it has voluntarily recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) for customers in the U.S. market.
On January 27, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Learn George Putnam's Turnaround Secrets
Turnaround Investing Blog
It can be tempting to look at a depressed stock and think, “it used to trade at 40 and now it’s at 8 – therefore it must be a bargain.” Unfortunately, the fact that a stock once traded at a higher price does not guarantee that it will ever get back there. One big reason that a stock trades so much lower than before: its earnings potential or assets have deteriorated. Without some fundamental improvement, the share price will continue to lag, or worse.
Market-Beating Profit: The 200+ Club
Turnaround stocks present a unique opportunity for savvy investors to buy in at bargain prices. Take a look at this list of just a few of our purchase recommendations that have realized a return rate of 200% or better:
* Bristow remains an our active purchase recommendation, currently as a "Hold," and 1,928% stock profit is as of 8/11/16.
Retail Turnaround Trio
MoneyShow.com interviewed George to learn more about his favorite value stock picks for today's market. In "Retail Turnaround Trio," Steve Halpern highlights three of The Turnaround Letter's recently-profiled retailers: JWN, TIF and SPLS.
Putnam notes, "Well the retailing sector is undergoing very fundamental change as people move away from the bricks and mortar mall doors to buying more and more online but that's not going to wipe out all of the old-fashioned retailers. Starting the middle of 2015, investors just moved away from retailers en masse and a number of them are trading at about half the level they were a year ago. We thought some of the higher quality names that definitely will be survivors looked interesting."
Learn more about these three retail stocks poised for a turnaround.
Copyright © All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing.